Esmo 2018 preview – Another first-line renal cancer showdown
Once again Europe’s premier oncology meeting provides the perfect venue for big pharmas including Pfizer, Roche and Astrazeneca to showcase important pivotal study results, among which another renal cancer battle could be the highlight.
